Loading
Vor Biopharma Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Jan 2025.
Vor Biopharma Inc.: what insiders have been doing
Every trade that managers of Vor Biopharma Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 3 insiders published 25 filings.
Only sales appear on the open market, 20 sales in all totalling €48.6M, filed by 2 insiders. Biggest ticket of the year: €7.7M, sold by RA Capital Management, L.P. and made public on 6 April 2026.
With 25 filings in twelve months, the company is more active than the median of 19 filings across the 5,808 companies we follow on the same exchange. The full history, which starts in 2021, counts 1 purchase against 37 sales. The 10-K for the year ended 31 December 2025 shows -696.0 m USD of net income.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
122
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
€61M
37 ops. · all time
Who traded when
BuySaleRA Capital Management, L.P.20 sales
Reprogrammed Interchange LLC1 buy12 sales
Eyal C. Attar3 sales
Since the insiders bought
- -59.9%Entry US$26.40 · Close at T+365 US$10.58
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Vor Biopharma Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$39.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$19.06
Analyst consensus
8 analystsStrong buy
US$27.00Target US$39.00(+105%)US$50.00
Income statement
EBITDA-US$368.8M
Net income-US$696M0.0% margin
Valuation
PER (trailing)0.1x
PER (forward)-5.0x
Beta1.78
Balance sheet & cash
Market capUS$1B
Total debtUS$3M
Free Cash Flow-US$143.7M
Profitability & ownership
ROA-21.4%
% insiders9.3%
% institutions86.8%
Last declaration on 5 October 2026
Declarations122 total
500 shares@ US$12.800.0006% mcap0.0% of flowCommon StockSEC:0001231919-26-001426:0
1,500 shares@ US$3.7360.0005% mcap0.0% of flowCommon StockSEC:0001231919-26-001102:0
2,100,000 shares@ US$0.0020.0004% mcap0.0% of flowCommon StockSEC:0001231919-26-000776:0
213 shares@ US$19.750.0004% mcap0.0% of flowCommon StockSEC:0001231919-26-000776:1
165,150 shares@ US$15.770.19% mcap1.6% of flowCommon StockSEC:0001231919-26-000409:0
458,411 shares@ US$16.280.66% mcap4.6% of flowCommon StockSEC:0001231919-26-000385:0
171,963 shares@ US$15.770.24% mcap1.7% of flowCommon StockSEC:0001231919-26-000385:1
53,644 shares@ US$16.010.076% mcap0.5% of flowCommon StockSEC:0001231919-26-000355:2
530,610 shares@ US$16.150.76% mcap5.2% of flowCommon StockSEC:0001231919-26-000355:0
153,735 shares@ US$15.970.22% mcap1.5% of flowCommon StockSEC:0001231919-26-000355:1
353,242 shares@ US$16.323.6% of flowCommon StockSEC:0001231919-26-000333:0
130,862 shares@ US$16.911.4% of flowCommon StockSEC:0001231919-26-000333:1
135,201 shares@ US$16.591.4% of flowCommon StockSEC:0001231919-26-000333:2
828 shares@ US$15.750.0012% mcap0.0% of flowCommon StockSEC:0001231919-26-000333:3
1,525 shares@ US$19.060.0% of flowCommon StockSEC:0001231919-26-000320:1
44,728 shares@ US$17.310.5% of flowCommon StockSEC:0001231919-26-000320:3
258,475 shares@ US$18.232.9% of flowCommon StockSEC:0001231919-26-000320:0
537,754 shares@ US$16.515.5% of flowCommon StockSEC:0001231919-26-000320:2
6,775 shares@ US$18.500.1% of flowCommon StockSEC:0001231919-26-000320:4
4,625,346 shares@ US$10.8130.6% of flowCommon StockSEC:0001231919-25-000644:0
694,137 shares0Common StockSEC:0001511034-25-000006:0
87,828 shares@ US$27.101.5% of flowCommon StockSEC:0001231919-25-000395:0
76,880 shares@ US$28.011.3% of flowCommon StockSEC:0001231919-25-000359:0
70,366 shares@ US$29.631.3% of flowCommon StockSEC:0001231919-25-000342:0
24,689 shares@ US$30.22077.1% of flowCommon StockSEC:0002050755-25-000019:0
25 of 122 declarations
About Vor Biopharma Inc.
Vor Biopharma Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq Global Select Market under the ticker VOR. The company is headquartered in Boston, Massachusetts, United States. It was founded in December 2015 and began operations in February 2016. Vor is currently a clinical-stage biotech with no approved commercial products, which places it squarely in the high-risk, high-upside segment of the life sciences market. For investors, the company remains highly dependent on clinical execution, regulatory progress, and access to capital.
Vor Biopharma originally built its platform around blood-cancer programs and cell-engineering approaches, but its strategy has since shifted materially toward autoimmune disease. In June 2025, the company signed a license agreement with RemeGen that gives Vor exclusive rights, including sublicensing rights, to develop and commercialize telitacicept in all territories outside Greater China. RemeGen retains rights in mainland China, Hong Kong, Macau, and Taiwan. This transaction was transformative for Vor’s business model, because it effectively converted the company from a pre-commercial oncology-focused developer into an autoimmune franchise centered on one lead asset.
Read moreShow less
Today, Vor’s core program is telitacicept, a fusion protein designed to inhibit both BAFF and APRIL, two key signaling pathways involved in B-cell survival and autoimmune activity. The company’s lead development priorities are generalized myasthenia gravis (gMG) and Sjögren’s disease (SjD). The most recent annual report states that telitacicept is already approved in China for systemic lupus erythematosus, rheumatoid arthritis, and gMG, which provides external clinical validation of the mechanism. However, that does not reduce the regulatory risk in the United States or Europe, where the asset still needs to complete late-stage development and secure approvals.
From a competitive standpoint, Vor competes in a crowded biotech landscape where the main differentiator is often the quality of clinical data rather than commercial scale. The company’s potential edge lies in the dual BAFF/APRIL mechanism and in the fact that it can leverage prior Chinese trial data from RemeGen. Vor says it initiated a global Phase 3 study in SjD with first patient dosing in March 2026, recruiting patients across the United States, Europe, South America, and Asia. It is also advancing a global Phase 3 program in gMG.
Recent catalysts have been meaningful. In 2025, Vor finalized the RemeGen licensing deal and presented Phase 3 data at medical congresses. In March 2026, it dosed the first patient in its global SjD Phase 3 study. The company also announced a private placement in late March 2026, expected to generate about $75 million in gross proceeds. More recently, SEC Form 4 filings showed sales by RA Capital-related entities, which investors often monitor as a sentiment signal, although such transactions do not necessarily imply a change in the long-term thesis. Overall, Vor Biopharma remains a development-stage biotech on Nasdaq in the United States, with valuation primarily driven by the next clinical readouts and the company’s ability to finance execution through regulatory milestones.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
